Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Price Quote as of

Today's Trading

Day Low 5.85
Day High 6.14
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. Galectin Therapeutics, formerly known as Pro-Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks
ACCESSWIRE - Wed Jul 11, 6:45AM CDT
Wed Jul 11, 6:45AM CDT
Stock Research Monitor: GALT, KPTI, and LCI
Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis
GlobeNewswire - Wed Jun 27, 7:00AM CDT
GlobeNewswire - CMTX
Wed Jun 27, 7:00AM CDT
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the Company has received notice of issuance of U.S. Patent Number 9,968,631 titled "Method and Treatment of Pulmonary Fibrosis." The patent's principal claims cover method of use of GR-MD-02 as a means to treat pulmonary fibrosis. The patent is expected to provide broad protection for the use of GR-MD-02 for compositions, methods of using and methods of manufacturing compositions capable of treating pulmonary fibrosis. The patent coverage extends to 2032.
Company Profile for Galectin Therapeutics Inc.
BusinessWire - Fri Jun 22, 9:40AM CDT
BusinessWire - CMTX
Fri Jun 22, 9:40AM CDT
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug (GR-MD-02) is a carbohydrate drug that inhibits the galectin-3 protein that is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, a more advanced form of NASH-related fibrosis. This is one of the most common liver diseases and is believed to be amongst the largest drug development opportunities available today. As many as one in four people globally suffer from fatty liver disease, also known as NASH (non-alcoholic steatohepatitis), with a lifetime risk of approximately 20 million liver-related deaths among fatty liver disease patients currently alive. Currently, the only treatment for patients with NASH and cirrhosis is a liver transplant. The potential market opportunity for drugs targeting NASH and cirrhosis is projected by analysts to be $35 - $40B worldwide by 2025. Additional exploratory development programs are in combination immunotherapy for advanced melanoma and other malignancies. Galectin seeks to leverage extensive scientific and development expertise, as well as established relationships with external sources, to achieve cost-effective and efficient development.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 5.80 +3.79% increase
on 07/17/18
Period Open:9.16
Price movement based on the high, low and last over the given period.
9.19 -34.49% decrease
on 06/19/18
-3.14 (-34.28%) decrease
since 06/18/18
3-Month 3.10 +94.19% increase
on 05/08/18
Period Open:3.37
Price movement based on the high, low and last over the given period.
9.49 -36.56% decrease
on 06/18/18
+2.65 (+78.64%) increase
since 04/18/18
52-Week 1.28 +370.31% increase
on 12/05/17
Period Open:2.29
Price movement based on the high, low and last over the given period.
9.49 -36.56% decrease
on 06/18/18
+3.73 (+162.88%) increase
since 07/18/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement